Michela Gabaldo is Head, Alliance Management & Regulatory Affairs at Fondazione Telethon in Milan (Italy) supporting the 2 internal Scientific Institutes SR-TIGET (San Raffaele-Telethon Institute for gene therapy) and TIGEM (Telethon Institute of Genetics and Medicine) through the early development up to the registration and market access of the gene therapy programs developed both internally and in partnership with relevant pharmaceutical industries.
She has 20 years of experience in drug development spanning from chemicals up to ATMP. She joined Telethon in 2011 where she manages gene therapy projects at different stages of development ranging from preclinical, to clinical, to registration and market access.
Winner of 2017 edition of TopRA Award in the Future category, Michela offers up to date knowledge of the most recent regulations in ATMPs and Orphans.
She’s currently a member of the IRDiRC (International Rare Disease Research Consortium) Therapies Scientific Committee.